Structure Therapeutics shares surge after positive results in weight-loss trial, $300 million private placement
Structure Therapeutics Inc.'s American depositary receipts (GPCR) jumped more than 90% premarket on Friday after the company announced positive results from an early-stage trial of a weight-loss treatment and a $300 million private placement. The company's oral GLP-1 receptor agonist, GSBR-1290, resulted in placebo-adjusted weight loss of up to 5% in healthy patients with obesity or overweight after 28 days, the company said in a release. Structure said it continues to plan the launch of a phase 2b study of the treatment in type 2 diabetes next year. The company on Friday also announced a $300 million private placement financing, with "participation from a number of large healthcare dedicated institutional and mutual fund investors." The proceeds will go toward accelerating GSBR-1290 development as well as other programs from the company's oral incretin franchise, Structure CEO Raymond Stevens said in a statement.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-29-23 0802ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks
-
After Earnings, Is Disney Stock a Buy, a Sell, or Fairly Valued?
-
Home Depot Earnings: Macro Factors Pinch Demand, but Long-Term Outlook Intact
-
Tariffs On Chinese EVs Offer US Automakers a Chance to Capture Demand
-
The Best REITs to Buy
-
3 Hot Stocks to Buy That Still Look Undervalued
-
After Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?